Hospital
Mercy Catholic Medical Center of Southeastern PA
Mercy Catholic Medical Center of Southeastern PA was paid $27.84M by Medicaid between Feb 2018 and Dec 2024, across 214 billing codes. Its largest line is 99283, emergency room visit (moderate) — 25% of everything it billed.
33Billing provider infoMERCY CATHOLIC MEDICAL CENTER OF SOUTHEASTERN PA
DARBY, PA 19023
DARBY, PA 19023
33aNPI1730173550assigned 09/08/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$27.84M
24GClaims227,862
24DCodes billed214
24AFirst – last monthFeb 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#8 of 154
Median peer was paid$2.82M
This provider vs. median9.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CUMMINGS, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 133 | $546.97 | |
| 2019 | 476 | $92K | |
| 2020 | 31,486 | $2.62M | |
| 2021 | 78,632 | $9.88M | |
| 2022 | 24,257 | $5.74M | |
| 2023 | 48,164 | $5.64M | |
| 2024incomplete | 44,714 | $3.87M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 25,327 | 24,411 | $6.85M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 17,543 | 16,741 | $5.41M |
| G0378 | Hospital observation service, per hour | 14% | 2,206 | 1,775 | $3.91M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.5% | 6,949 | 6,538 | $2.36M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.8% | 8,743 | 8,469 | $2.17M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 5.5% | 985 | 928 | $1.52M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 5.3% | 936 | 879 | $1.48M |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 3.0% | 7,539 | 2,110 | $828K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 223 | 213 | $278K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,273 | 2,144 | $223K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,115 | 1,105 | $222K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 798 | 769 | $166K |
202 more codes
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 675 | $147K |
| 73564 | <1% | 2,831 | $141K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 640 | $121K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 606 | $108K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,980 | $100K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 343 | $84K |
| 76830 | Ultrasound, transvaginal | <1% | 647 | $78K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 469 | $77K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,964 | $72K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 749 | $71K |
| 77066 | Tomosynthesis, mammo | <1% | 279 | $59K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 745 | $56K |
| 92557 | <1% | 759 | $51K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 88 | $49K |
| 94729 | <1% | 694 | $48K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,614 | $47K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,094 | $46K |
| 93975 | <1% | 310 | $45K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,618 | $44K |
| 76642 | <1% | 421 | $42K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,442 | $39K |
| 80053 | Comprehensive metabolic panel | <1% | 4,188 | $38K |
| 94727 | <1% | 687 | $35K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,908 | $33K |
| 85027 | <1% | 2,073 | $32K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 66 | $29K |
| 77065 | Tomosynthesis, mammo | <1% | 151 | $26K |
| 76770 | <1% | 229 | $23K | |
| 74183 | <1% | 28 | $22K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 154 | $21K |
| 93970 | <1% | 136 | $21K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 915 | $20K |
| 92567 | <1% | 773 | $20K | |
| 93017 | <1% | 199 | $19K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 559 | $19K |
| 73030 | <1% | 543 | $18K | |
| 71250 | <1% | 157 | $17K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,059 | $17K |
| 94375 | <1% | 252 | $16K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 110 | $15K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 871 | $15K |
| 97162 | <1% | 277 | $14K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 38 | $14K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 113 | $14K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 154 | $14K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,838 | $14K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 40 | $13K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 219 | $13K |
| 73610 | <1% | 390 | $12K | |
| 73502 | <1% | 299 | $12K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,790 | $12K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,529 | $11K |
| 86900 | <1% | 701 | $11K | |
| 93325 | <1% | 54 | $10K | |
| 93971 | <1% | 112 | $10K | |
| 80061 | Lipid panel | <1% | 781 | $10K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 527 | $9K |
| 85610 | <1% | 1,577 | $8K | |
| 77062 | <1% | 102 | $8K | |
| 94060 | <1% | 226 | $8K | |
| 97597 | <1% | 130 | $8K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 501 | $8K |
| 96417 | <1% | 54 | $7K | |
| 73630 | <1% | 379 | $7K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 664 | $7K |
| 80050 | General health panel | <1% | 67 | $7K |
| 73130 | <1% | 345 | $6K | |
| 72100 | <1% | 119 | $6K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 87 | $6K |
| 72110 | <1% | 104 | $5K | |
| 87081 | <1% | 749 | $5K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,615 | $5K |
| 83735 | <1% | 3,609 | $5K | |
| C1769 | Guide wire | <1% | 31 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 764 | $5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 904 | $5K |
| 93350 | <1% | 28 | $4K | |
| 80076 | <1% | 1,649 | $4K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 101 | $4K |
| 82805 | <1% | 414 | $4K | |
| 97161 | <1% | 90 | $4K | |
| 76981 | <1% | 67 | $4K | |
| 73110 | <1% | 174 | $4K | |
| 93320 | <1% | 41 | $4K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 93 | $4K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 529 | $4K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 586 | $3K |
| 73562 | <1% | 69 | $3K | |
| 80177 | <1% | 135 | $3K | |
| 96415 | <1% | 35 | $3K | |
| 81001 | <1% | 732 | $3K | |
| 71271 | <1% | 12 | $3K | |
| 83880 | <1% | 438 | $3K | |
| 36600 | <1% | 414 | $3K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 44 | $3K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 460 | $3K |
| 84484 | <1% | 1,586 | $2K | |
| 80164 | <1% | 56 | $2K | |
| 95806 | <1% | 13 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 546 | $2K |
| 83690 | <1% | 1,677 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 50 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 140 | $2K |
| 84702 | <1% | 408 | $2K | |
| 0011A | <1% | 41 | $2K | |
| 85730 | <1% | 826 | $2K | |
| 76536 | <1% | 14 | $2K | |
| 93923 | <1% | 12 | $1K | |
| 0012A | <1% | 23 | $1K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 292 | $1K |
| 86885 | <1% | 198 | $1K | |
| 97163 | <1% | 16 | $1K | |
| 96367 | <1% | 29 | $1K | |
| 82728 | <1% | 89 | $1K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 12 | $998.16 |
| 82550 | <1% | 817 | $983.22 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 649 | $980.47 |
| 82248 | <1% | 565 | $961.23 | |
| 84466 | <1% | 48 | $910.83 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,495 | $901.06 |
| 93041 | <1% | 916 | $864.96 | |
| 84100 | <1% | 1,074 | $795.46 | |
| 88342 | <1% | 187 | $776.36 | |
| 82607 | <1% | 47 | $762.38 | |
| 36591 | <1% | 33 | $725.01 | |
| 86901 | <1% | 232 | $643.93 | |
| 86140 | <1% | 103 | $620.76 | |
| 82043 | <1% | 80 | $619.55 | |
| 83540 | <1% | 64 | $617.98 | |
| 85652 | <1% | 94 | $611.97 | |
| 87077 | <1% | 117 | $598.38 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 53 | $566.78 |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 133 | $546.97 |
| 82330 | <1% | 391 | $535.42 | |
| 90715 | <1% | 40 | $522.23 | |
| 83605 | <1% | 423 | $516.22 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,151 | $512.30 |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 223 | $501.07 |
| 81025 | <1% | 1,614 | $495.39 | |
| 76857 | <1% | 12 | $477.38 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,051 | $473.42 |
| 84153 | <1% | 27 | $471.79 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 12 | $426.58 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 220 | $399.23 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 417 | $362.61 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 511 | $349.24 |
| 97116 | <1% | 21 | $316.32 | |
| 84439 | <1% | 50 | $312.72 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 58 | $310.96 |
| 81003 | <1% | 194 | $300.26 | |
| 82077 | <1% | 229 | $233.10 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,617 | $220.09 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 332 | $217.05 |
| 87186 | <1% | 24 | $213.60 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 12 | $212.12 |
| 73590 | <1% | 15 | $204.29 | |
| 85014 | <1% | 72 | $192.85 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 889 | $188.56 |
| 86850 | <1% | 26 | $168.51 | |
| 82746 | <1% | 12 | $164.02 | |
| 76801 | <1% | 13 | $153.56 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 928 | $153.29 |
| 82947 | <1% | 12 | $126.76 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,463 | $122.13 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,089 | $98.93 |
| 80051 | <1% | 37 | $90.42 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 91 | $81.00 |
| 94760 | <1% | 12 | $65.73 | |
| 85379 | <1% | 51 | $57.47 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,726 | $53.17 |
| 88304 | <1% | 80 | $52.67 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,506 | $45.63 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 586 | $42.26 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 356 | $30.09 |
| A9270 | Non-covered item or service | <1% | 5,247 | $14.19 |
| 84295 | <1% | 86 | $13.06 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,318 | $12.90 |
| 84132 | <1% | 91 | $12.74 | |
| 82435 | <1% | 86 | $12.74 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,253 | $10.46 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 157 | $5.67 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 274 | $2.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 116 | $0.80 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 1,010 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 417 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 273 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 712 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 1,671 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 565 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 274 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 27 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 15 | $0.00 |
| J2251 | Injection, midazolam in 0.9% sodium chloride, intravenous, not therapeutically equivalent to j2250, 1 mg | 0% | 25 | $0.00 |
| 87400 | 0% | 14 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 23 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 64 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 23 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 373 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 159 | $0.00 |
| 96376 | 0% | 41 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 484 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 73 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCUMMINGS, KIMBERLY (VP, FINANCE AND CFO)
Parent organizationMERCY CATHOLIC MEDICAL CENTER OF SOUTHEASTERN PA
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.